Personalized medicine. Closing the gap between knowledge and clinical practice

详细信息    查看全文

• 作者：Juan-Manuel Anaya^a ; ^{anayajm@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Carolina Duarte-Rey^a ; Juan C. Sarmiento-Monroy^a ; David Bardey^b ; ^c ; John Castiblanco^a ; ^d ; Adriana Rojas-Villarraga^a
• 关键词：PM ; Personalized medicine ; AD ; Autoimmune disease ; RA ; Rheumatoid Arthritis ; T1D ; Type 1 Diabetes Mellitus ; ACPA ; anti-citrullinated peptides antibodies ; RF ; rheumatoid factor ; DMARD ; disease-modifying antirheumatic drug ; HAQ ; Health Assessment Questionnaire ; DAS28 ; high disease activity score
• 刊名：Autoimmunity Reviews
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：15
• 期：8
• 页码：833-842
• 全文大小：814 K

文摘

Personalized medicine encompasses a broad and evolving field informed by a patient distinctive information and biomarker profile. Although terminology is evolving and some semantic interpretations exist (e.g., personalized, individualized, precision), in a broad sense personalized medicine can be coined as: “To practice medicine as it once used to be in the past using the current biotechnological tools.” A humanized approach to personalized medicine would offer the possibility of exploiting systems biology and its concept of P5 medicine, where predictive factors for developing a disease should be examined within populations in order to establish preventive measures on at-risk individuals, for whom healthcare should be personalized and participatory. Herein, the process of personalized medicine is presented together with the options that can be offered in health care systems with limited resources for diseases like rheumatoid arthritis and type 1 diabetes.